Utrecht (The Netherlands) and Mont-Saint-Guibert (Belgium) – Nyxoah S.A., a healthtech company focused on the development of innovative solutions and services for sleep related disorders, announced today the publication of data from the BLAST OSA (BiLAteral Hypoglossal Nerve Stimulation for Treatment of Obstructive Sleep Apnea) clinical study for the Genio® system in the European Respiratory Journal. These data demonstrate that treatment with the Genio® system was safe and effective, and resulted in significant improvement in patients’ Quality of Life measurements.
Key results from the BLAST OSA study include a significant reduction in OSA severity both in terms of Apnea Hypopnea Index (AHI) and Oxygen Desaturation Index (ODI); a significant improvement of daytime sleepiness; and sleep-related quality of life. The number of bed partners reporting loud, very intense snoring, or leaving the bedroom due to participant snoring decreased from 96% to 35% while 91% of participants reported using the device more than 5 days per week.
The Genio® system is the world’s first and only battery-free, leadless and minimally invasive neurostimulator, capable of delivering bilateral hypoglossal nerve stimulation in moderate to severe Obstructive Sleep Apnea (OSA) patients who have not tolerated, have failed or refused Positive Airway Pressure (PAP) therapy.
Nyxoah is a healthtech company focused on the development of innovative, neurostimulation-based solutions and services for sleep related disorders. Nyxoah’s lead technology is the Genio® system, the world’s first and only, battery-free, leadless and minimally invasive implanted neurostimulator that treats the underlying cause of Obstructive Sleep Apnea (OSA), a market worth approximately $10bn in the US alone. The Genio® system received its European CE Mark in March 2019 and a US trial programme for FDA approval is in preparation.
Nyxoah was co-founded in 2009 by Robert Taub, a renowned entrepreneur and serial investor in the life sciences sector. Since its inception, the Company has raised over €50m from M. Taub and private investors, Gilde Healthcare, a high quality, healthcare specialist international investor, SRIW, the Regional Investment Company of Wallonia and Cochlear, an international medical device company which develops a range of implantable hearing solutions. For more information, visit the company’s website at www.nyxoah.com.
About Gilde Healthcare
Gilde Healthcare is a specialized European healthcare investor managing € 1 billion ($ 1.2 billion) across two fund strategies: venture & growth capital and private equity. Gilde Healthcare’s venture & growth capital fund invests in health tech and therapeutics. The venture & growth companies are based in Europe and North America. Gilde Healthcare’s private equity fund invests in profitable European lower mid-market healthcare companies with a focus on the Benelux and DACH region. The private equity fund targets healthcare providers, suppliers of medical products and service providers in the healthcare market. For more information, visit the company’s website at www.gildehealthcare.com.